AstraZeneca is increasingly integrating artificial intelligence into its biologic drug development process, accelerating the design and testing of new medicines. The company uses AI to computationally generate and prioritize candidate molecules, reducing cycle times and boosting productivity in research and development, according to Puja Sapra, senior vice president and head of R&D biologics engineering and oncology targeted discovery at AstraZeneca, as reported by technologyreview.com.
The process follows a build-measure-learn loop where AI predicts which molecular designs are most likely to succeed, allowing scientists to focus laboratory resources on the most promising candidates. This computational enhancement spans the entire workflow, from design to testing and analysis, enabling faster iteration and innovation in biologic drug discovery. AstraZeneca is actively expanding its engineering teams to further embed AI capabilities in its R&D operations.
Biologic medicines, which are therapies made from engineered proteins, present complex challenges due to the need to identify molecules that bind correctly, remain stable in the body, and can be manufactured at scale. Traditional drug development is costly and failure-prone, often taking many years. AI's role in speeding up these processes is becoming central in pharmaceutical research, with AstraZeneca exemplifying how computational tools can transform biologic drug discovery.
Puja Sapra highlighted that AI integration has shortened cycle times while increasing innovation and productivity in drug development. AstraZeneca's approach demonstrates a significant shift toward computationally enhanced R&D, reflecting broader trends in the pharmaceutical industry toward leveraging AI for faster and more efficient biologic medicine design.